Prospective clinical studies involving larger NSCLC patient cohorts and diverse ethnic groups are required to further validate MZT2B as a reliable diagnostic, prognostic, or predictive biomarker. This evidence concerns the gene MZT2B and non-small cell lung carcinoma.